Last updated on August 2020

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

Brief description of study

The purpose of the trial is to determine the maximum tolerated dose and to establish the safety profile of HuMax-AXL-ADC in a mixed population of patients with specified solid tumors

Detailed Study Description

The trial consists of two parts; a dose escalation part (phase I, first in- human (FIH)) and an expansion part (phase IIa).

The dose escalation part has two dose escalation arms: the first arm investigates a once every 3 weeks (1Q3W) dosing schedule and the second arm investigates a three administrations over 4 weeks (3Q4W) dosing schedule.

The Expansion part of the trial will further explore the recommended phase 2 dose and dosing regimens of HuMax-AXL-ADC as determined in Part 1

Clinical Study Identifier: NCT02988817

Find a site near you

Start Over

Mayo Clinic Scottsdale

Phoenix, AZ United States
  Connect »

Mayo Clinic Jacksonville

Jacksonville, FL United States
  Connect »

University of Iowa

Iowa City, IA United States
  Connect »

Mayo Clinic Rochester

Rochester, MN United States
  Connect »

NYU Medical Center

New York, NY United States
  Connect »

Duke Cancer Institute

Durham, NC United States
  Connect »

Fox Chase Cancer Center

Philadelphia, PA United States
  Connect »

MD Anderson

Houston, TX United States
  Connect »

Huntsman Cancer Institute

Salt Lake City, UT United States
  Connect »

Moffitt Cancer Center

Tampa, FL United States
  Connect »

Washington University

Saint Louis, MO United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.